Silo Pharma, Inc. (SILO) Stock Price & Analysis

Silo Pharma, Inc. (SILO) fell 2.04% to USD 2.4 as of September 8, 2026 at 12:46 UTC, according to Nexqual real-time market data.

SILO last closed at USD 2.4; the session ranged USD 2.21–2.5 on volume of 34,954 shares. Market capitalization is —, with a 52-week range of USD 2.21–15.15 (NCM). Source: Nexqual, September 8, 2026 at 12:46 UTC.

Key Statistics (as of September 8, 2026 at 12:46 UTC)

Technical Analysis (SILO)

Nexqual's technical model rates SILO "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 12:46 UTC.

From Silo Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

• Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.   Fibromyalgia affects approximately 4 million U.S. adults (2% of the population).
• Our policy is to actively seek the broadest intellectual property protection possible for our products, proprietary information and proprietary technology through a combination of contractual arrangements and patents.
• In addition, we have established business procedures designed to maintain the confidentiality of our proprietary information, including the use of confidentiality agreements with employees, independent contractors, consultants and entities with which we conduct business.   To date, the intellectual property owned and licensed by us includes 5 issued patents and 20 pending patent applications in 14 patent families in the U.S. and abroad.

Partnerships

• SPC-14 was developed under a sponsored research agreement with Columbia University See "Investigator-Sponsored Study Agreements between the Company and Vendors---Sponsored Research Agreement with Columbia University for the Study of Ketamine in Combination with Other Drugs for Treatment of Alzheimer's and Depression Disorders." We have exclusive global rights to develop and commercialize SPC-14, pursuant to and that certain exclusive license agreement entered into with Columbia on July 1, 2024.
• We are actively collaborating with Columbia University, holding exclusive global rights to develop and commercialize SPC-15, pursuant to and that certain exclusive license agreement entered into with Columbia on July 1, 2024.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:46 UTC. This page is informational and not investment advice.